Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + lapatinib + octreotide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination therapy consisting of capecitabine, lapatinib, and octreotide. Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Capecitabine is an oral chemotherapy drug that is converted to 5-fluorouracil in the body. Octreotide LAR (long-acting formulation) is added as a prophylactic treatment to prevent or reduce diarrhea, which is a common side effect of the lapatinib-capecitabine combination. This regimen is used for patients with HER2-positive advanced or metastatic breast cancer who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)TS (Thymidylate synthase)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on capecitabine + lapatinib + octreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + lapatinib + octreotide.